A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors
Start Date
6/24/2024
Completion Date
10/1/2027
Summary
This is a Phase 1, first-in-human, open-label, multi-center study with the aim of exploring the safety, tolerability, PK, and preliminary anti-tumor activity of ANS014004 as a single agent in participants with locally advanced or metastatic solid tumors.
Eligibility Criteria
Age Range: 18 years to No maximum
Interventions
ANS014004
Conditions
Locations
University of California, San Diego
San Diego, California 92093
United States
Sarah Cannon Research Institute
Denver, Colorado 80218
United States
Advent Health
Orlando, Florida 32804
United States
Henry Ford Health Cancer
Detroit, Michigan 48202
United States
NYU Langone Health
New York, New York 10003
United States
The University of Texas - MD Anderson Cancer Center
Houston, Texas 77030
United States
NEXT Oncology, Virginia
Fairfax, Virginia 22031
United States
Swedish Cancer Institute
Seattle, Washington 98195
United States
BC Cancer Vancouver Centre
Vancouver, British Columbia
Canada
Princess Margaret Cancer Centre
Toronto, Ontario
Canada
Beijing Chest Hospital
Beijing, Beijing Municipality 101149
China
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang 150010
China
Henan Cancer Hospital
Zhengzhou, Henan 450008
China
Shandong Cancer Hospital
Jinan, Shandong 250117
China
Shanghai Chest Hospital
Shanghai, Shanghai Municipality 200030
China